United States Oncology Biosimilars Market Report 2016

September 2016 | 122 pages | ID: U6249F575BEEN
QYResearch

Abstracts

Notes:

Sales, means the sales volume of Oncology Biosimilars

Revenue, means the sales value of Oncology Biosimilars

This report studies sales (consumption) of Oncology Biosimilars in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering

• 3SBio
• Biocon
• BioXpress Therapeutics
• Boehringer Ingelheim
• Celltrion
• Coherus Biosciences
• Dr. Reddy’s Laboratories
• Hospira
• Intas Pharmaceuticals
• Merck Serono
• Mylan
• Novartis (Sandoz)
• Pfizer
• Wockhardt

Split by product types, with sales, revenue, price, market share and growth rate of each type, can be divided into

• Type I
• Type II
• Type III

Split by applications, this report focuses on sales, market share and growth rate of Oncology Biosimilars in each application, can be divided into

• Application 1
• Application 2
• Application 3

Contents

United States Oncology Biosimilars Market Report 2016

1 ONCOLOGY BIOSIMILARS OVERVIEW

1.1 Product Overview and Scope of Oncology Biosimilars
1.2 Classification of Oncology Biosimilars
  1.2.1 Type I
  1.2.2 Type II
  1.2.3 Type III
1.3 Application of Oncology Biosimilars
  1.3.1 Application
  1.3.2 Application
  1.3.3 Application
1.4 United States Market Size Sales (Value) and Revenue (Volume) of Oncology Biosimilars (2011-2021)
  1.4.1 United States Oncology Biosimilars Sales and Growth Rate (2011-2021)
  1.4.2 United States Oncology Biosimilars Revenue and Growth Rate (2011-2021)

2 UNITED STATES ONCOLOGY BIOSIMILARS COMPETITION BY MANUFACTURERS

2.1 United States Oncology Biosimilars Sales and Market Share of Key Manufacturers (2015 and 2016)
2.2 United States Oncology Biosimilars Revenue and Share by Manufactures (2015 and 2016)
2.3 United States Oncology Biosimilars Average Price by Manufactures (2015 and 2016)
2.4 Oncology Biosimilars Market Competitive Situation and Trends
  2.4.1 Oncology Biosimilars Market Concentration Rate
  2.4.2 Oncology Biosimilars Market Share of Top 3 and Top 5 Manufacturers
  2.4.3 Mergers & Acquisitions, Expansion

3 UNITED STATES ONCOLOGY BIOSIMILARS SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (2011-2016)

3.1 United States Oncology Biosimilars Sales and Market Share by Type (2011-2016)
3.2 United States Oncology Biosimilars Revenue and Market Share by Type (2011-2016)
3.3 United States Oncology Biosimilars Price by Type (2011-2016)
3.4 United States Oncology Biosimilars Sales Growth Rate by Type (2011-2016)

4 UNITED STATES ONCOLOGY BIOSIMILARS SALES (VOLUME) BY APPLICATION (2011-2016)

4.1 United States Oncology Biosimilars Sales and Market Share by Application (2011-2016)
4.2 United States Oncology Biosimilars Sales Growth Rate by Application (2011-2016)
4.3 Market Drivers and Opportunities

5 UNITED STATES ONCOLOGY BIOSIMILARS MANUFACTURERS PROFILES/ANALYSIS

5.1 3SBio
  5.1.1 Company Basic Information, Manufacturing Base and Competitors
  5.1.2 Oncology Biosimilars Product Type, Application and Specification
    5.1.2.1 Type I
    5.1.2.2 Type II
  5.1.3 3SBio Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2011-2016)
  5.1.4 Main Business/Business Overview
5.2 Biocon
  5.2.2 Oncology Biosimilars Product Type, Application and Specification
    5.2.2.1 Type I
    5.2.2.2 Type II
  5.2.3 Biocon Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2011-2016)
  5.2.4 Main Business/Business Overview
5.3 BioXpress Therapeutics
  5.3.2 Oncology Biosimilars Product Type, Application and Specification
    5.3.2.1 Type I
    5.3.2.2 Type II
  5.3.3 BioXpress Therapeutics Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2011-2016)
  5.3.4 Main Business/Business Overview
5.4 Boehringer Ingelheim
  5.4.2 Oncology Biosimilars Product Type, Application and Specification
    5.4.2.1 Type I
    5.4.2.2 Type II
  5.4.3 Boehringer Ingelheim Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2011-2016)
  5.4.4 Main Business/Business Overview
5.5 Celltrion
  5.5.2 Oncology Biosimilars Product Type, Application and Specification
    5.5.2.1 Type I
    5.5.2.2 Type II
  5.5.3 Celltrion Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2011-2016)
  5.5.4 Main Business/Business Overview
5.6 Coherus Biosciences
  5.6.2 Oncology Biosimilars Product Type, Application and Specification
    5.6.2.1 Type I
    5.6.2.2 Type II
  5.6.3 Coherus Biosciences Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2011-2016)
  5.6.4 Main Business/Business Overview
5.7 Dr. Reddy’s Laboratories
  5.7.2 Oncology Biosimilars Product Type, Application and Specification
    5.7.2.1 Type I
    5.7.2.2 Type II
  5.7.3 Dr. Reddy’s Laboratories Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2011-2016)
  5.7.4 Main Business/Business Overview
5.8 Hospira
  5.8.2 Oncology Biosimilars Product Type, Application and Specification
    5.8.2.1 Type I
    5.8.2.2 Type II
  5.8.3 Hospira Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2011-2016)
  5.8.4 Main Business/Business Overview
5.9 Intas Pharmaceuticals
  5.9.2 Oncology Biosimilars Product Type, Application and Specification
    5.9.2.1 Type I
    5.9.2.2 Type II
  5.9.3 Intas Pharmaceuticals Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2011-2016)
  5.9.4 Main Business/Business Overview
5.10 Merck Serono
  5.10.2 Oncology Biosimilars Product Type, Application and Specification
    5.10.2.1 Type I
    5.10.2.2 Type II
  5.10.3 Merck Serono Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2011-2016)
  5.10.4 Main Business/Business Overview
5.11 Mylan
5.12 Novartis (Sandoz)
5.13 Pfizer
5.14 Wockhardt

6 ONCOLOGY BIOSIMILARS MANUFACTURING COST ANALYSIS

6.1 Oncology Biosimilars Key Raw Materials Analysis
  6.1.1 Key Raw Materials
  6.1.2 Price Trend of Key Raw Materials
  6.1.3 Key Suppliers of Raw Materials
  6.1.4 Market Concentration Rate of Raw Materials
6.2 Proportion of Manufacturing Cost Structure
  6.2.1 Raw Materials
  6.2.2 Labor Cost
  6.2.3 Manufacturing Expenses
6.3 Manufacturing Process Analysis of Oncology Biosimilars

7 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

7.1 Oncology Biosimilars Industrial Chain Analysis
7.2 Upstream Raw Materials Sourcing
7.3 Raw Materials Sources of Oncology Biosimilars Major Manufacturers in 2015
7.4 Downstream Buyers

8 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

8.1 Marketing Channel
  8.1.1 Direct Marketing
  8.1.2 Indirect Marketing
  8.1.3 Marketing Channel Development Trend
8.2 Market Positioning
  8.2.1 Pricing Strategy
  8.2.2 Brand Strategy
  8.2.3 Target Client
8.3 Distributors/Traders List

9 MARKET EFFECT FACTORS ANALYSIS

9.1 Technology Progress/Risk
  9.1.1 Substitutes Threat
  9.1.2 Technology Progress in Related Industry
9.2 Consumer Needs/Customer Preference Change
9.3 Economic/Political Environmental Change

10 UNITED STATES ONCOLOGY BIOSIMILARS MARKET FORECAST (2016-2021)

10.1 United States Oncology Biosimilars Sales, Revenue Forecast (2016-2021)
10.2 United States Oncology Biosimilars Sales Forecast by Type (2016-2021)
10.3 United States Oncology Biosimilars Sales Forecast by Application (2016-2021)
10.4 Oncology Biosimilars Price Forecast (2016-2021)

11 RESEARCH FINDINGS AND CONCLUSION

12 APPENDIX

Author List
Disclosure Section
Research Methodology
Data Source
Disclaimer

List Of Tables

LIST OF TABLES AND FIGURES

Figure Picture of Oncology Biosimilars
Table Classification of Oncology Biosimilars
Figure United States Sales Market Share of Oncology Biosimilars by Type in 2015
Table Application of Oncology Biosimilars
Figure United States Sales Market Share of Oncology Biosimilars by Application in 2015
Figure United States Oncology Biosimilars Sales and Growth Rate (2011-2021)
Figure United States Oncology Biosimilars Revenue and Growth Rate (2011-2021)
Table United States Oncology Biosimilars Sales of Key Manufacturers (2015 and 2016)
Table United States Oncology Biosimilars Sales Share by Manufacturers (2015 and 2016)
Figure 2015 Oncology Biosimilars Sales Share by Manufacturers
Figure 2016 Oncology Biosimilars Sales Share by Manufacturers
Table United States Oncology Biosimilars Revenue by Manufacturers (2015 and 2016)
Table United States Oncology Biosimilars Revenue Share by Manufacturers (2015 and 2016)
Table 2015 United States Oncology Biosimilars Revenue Share by Manufacturers
Table 2016 United States Oncology Biosimilars Revenue Share by Manufacturers
Table United States Market Oncology Biosimilars Average Price of Key Manufacturers (2015 and 2016)
Figure United States Market Oncology Biosimilars Average Price of Key Manufacturers in 2015
Figure Oncology Biosimilars Market Share of Top 3 Manufacturers
Figure Oncology Biosimilars Market Share of Top 5 Manufacturers
Table United States Oncology Biosimilars Sales by Type (2011-2016)
Table United States Oncology Biosimilars Sales Share by Type (2011-2016)
Figure United States Oncology Biosimilars Sales Market Share by Type in 2015
Table United States Oncology Biosimilars Revenue and Market Share by Type (2011-2016)
Table United States Oncology Biosimilars Revenue Share by Type (2011-2016)
Figure Revenue Market Share of Oncology Biosimilars by Type (2011-2016)
Table United States Oncology Biosimilars Price by Type (2011-2016)
Figure United States Oncology Biosimilars Sales Growth Rate by Type (2011-2016)
Table United States Oncology Biosimilars Sales by Application (2011-2016)
Table United States Oncology Biosimilars Sales Market Share by Application (2011-2016)
Figure United States Oncology Biosimilars Sales Market Share by Application in 2015
Table United States Oncology Biosimilars Sales Growth Rate by Application (2011-2016)
Figure United States Oncology Biosimilars Sales Growth Rate by Application (2011-2016)
Table 3SBio Basic Information List
Table 3SBio Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2011-2016)
Figure 3SBio Oncology Biosimilars Sales Market Share (2011-2016)
Table Biocon Basic Information List
Table Biocon Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2011-2016)
Table Biocon Oncology Biosimilars Sales Market Share (2011-2016)
Table BioXpress Therapeutics Basic Information List
Table BioXpress Therapeutics Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2011-2016)
Table BioXpress Therapeutics Oncology Biosimilars Sales Market Share (2011-2016)
Table Boehringer Ingelheim Basic Information List
Table Boehringer Ingelheim Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2011-2016)
Table Boehringer Ingelheim Oncology Biosimilars Sales Market Share (2011-2016)
Table Celltrion Basic Information List
Table Celltrion Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2011-2016)
Table Celltrion Oncology Biosimilars Sales Market Share (2011-2016)
Table Coherus Biosciences Basic Information List
Table Coherus Biosciences Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2011-2016)
Table Coherus Biosciences Oncology Biosimilars Sales Market Share (2011-2016)
Table Dr. Reddy’s Laboratories Basic Information List
Table Dr. Reddy’s Laboratories Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2011-2016)
Table Dr. Reddy’s Laboratories Oncology Biosimilars Sales Market Share (2011-2016)
Table Hospira Basic Information List
Table Hospira Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2011-2016)
Table Hospira Oncology Biosimilars Sales Market Share (2011-2016)
Table Intas Pharmaceuticals Basic Information List
Table Intas Pharmaceuticals Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2011-2016)
Table Intas Pharmaceuticals Oncology Biosimilars Sales Market Share (2011-2016)
Table Merck Serono Basic Information List
Table Merck Serono Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2011-2016)
Table Merck Serono Oncology Biosimilars Sales Market Share (2011-2016)
Table Mylan Basic Information List
Table Mylan Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2011-2016)
Table Mylan Oncology Biosimilars Sales Market Share (2011-2016)
Table Novartis (Sandoz) Basic Information List
Table Novartis (Sandoz) Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2011-2016)
Table Novartis (Sandoz) Oncology Biosimilars Sales Market Share (2011-2016)
Table Pfizer Basic Information List
Table Pfizer Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2011-2016)
Table Pfizer Oncology Biosimilars Sales Market Share (2011-2016)
Table Wockhardt Basic Information List
Table Wockhardt Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2011-2016)
Table Wockhardt Oncology Biosimilars Sales Market Share (2011-2016)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Oncology Biosimilars
Figure Manufacturing Process Analysis of Oncology Biosimilars
Figure Oncology Biosimilars Industrial Chain Analysis
Table Raw Materials Sources of Oncology Biosimilars Major Manufacturers in 2015
Table Major Buyers of Oncology Biosimilars
Table Distributors/Traders List
Figure United States Oncology Biosimilars Production and Growth Rate Forecast (2016-2021)
Figure United States Oncology Biosimilars Revenue and Growth Rate Forecast (2016-2021)
Table United States Oncology Biosimilars Production Forecast by Type (2016-2021)
Table United States Oncology Biosimilars Consumption Forecast by Application (2016-2021)